According to previous studies, compared with chemotherapy, PD-1 inhibitor monotherapy has demonstrated greater antitumor efficacy as a second-line therapy for advanced ESCC with controllable safety [7]. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.